Status:
NOT_YET_RECRUITING
ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Leukemia, Myeloid
Eligibility:
All Genders
18-80 years
Brief Summary
"In daily clinical practice, 2022 ELN guidelines were used to predict response to conventional treatment and to guide the need for allogenic stem cell transplantation. But, the team has to underline t...
Eligibility Criteria
Inclusion
- Newly diagnosed AML
- At least 18 yo
- MENAFC (Middle East ern of North Coast of Africa) patients with HLA HLA \> 50%
- ECOG performance status of 0,1,2,3"
Exclusion
- Acute promyelocytic leukemia
- Patients alive at the start of the study who did not receive study information or who objected to the collection of data"
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06512610
Start Date
August 1 2024
End Date
January 1 2025
Last Update
July 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU NICE
Nice, Alpes Maritimes, France, 0600